b3f7d666-c19c-4dd3-94b7-b85877c8ea28
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 63.62765229295
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.480
- ALLOGRAFT_REJECTION+0.370
- G2M_CHECKPOINT+0.360
- HEDGEHOG_SIGNALING+0.340
- E2F_TARGETS+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- INFLAMMATORY_RESPONSE+0.310
- MYC_TARGETS_V2+0.310
- ANGIOGENESIS+0.300
- COMPLEMENT+0.240
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.420
- FATTY_ACID_METABOLISM-0.410
- CHOLESTEROL_HOMEOSTASIS-0.360
- P53_PATHWAY-0.350
- ADIPOGENESIS-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- PEROXISOME-0.240
- HEME_METABOLISM-0.220
- DNA_REPAIR-0.200
- GLYCOLYSIS-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168603 | — | — | 0.817 |
| 2 | TCGA-CQ-A4CB-01A-11R-A24Z-07 | — | — | 0.808 |
| 3 | BS_J1AB8PMA | medulloblastoma | — | 0.804 |
| 4 | TCGA-DK-A3WX-01A-22R-A22U-07 | — | — | 0.777 |
| 5 | 7c4477a6-c744-412a-8571-bfb62f0dc714 | — | — | 0.776 |
| 6 | TCGA-98-8023-01A-11R-2247-07 | — | cohortSQ1 | 0.776 |
| 7 | R263 | — | — | 0.773 |
| 8 | c56e13bb-f1b0-4ee3-85c1-807c7c3bcef9 | — | — | 0.770 |
| 9 | SRR8518214 | — | D | 0.770 |
| 10 | MNG1010 | — | — | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |